Stroke Disorder & Treatment Market Expects An Extensive Growth In Roi Till 2022

Market Scenario

The Global Stroke Disorder and Treatment Market is presumed to demonstrate a healthy CAGR during the forecast period (2016-2022) owing to the rising high blood pressure patients, asserts Market Research Future (MRFR).

Heart problems and brain problems are considered among most dangerous medical problems, and their treatments are considered to be most expensive. Heart strokes and brain strokes can strike any moment and can be fatal. Hence, the market offering treatment for it is always lucrative. Globally it is increasing rapidly. The major factor that drives the growth of this market is the increasing high blood pressure patients. Due to increasing alcoholism and patients with diabetes, cardiovascular diseases are increasing the growth of this disorder and the market offering its treatment.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1651

Stroke is referred to as the condition which occurs when clot is formed in the artery and oxygen supply is cut off. Brain cells thus get deprived of oxygen and start to die. Heart and brain strokes can strike any moment and can be fatal. Stroke is considered as one of the leading causes of death across the world with higher prevalence in the geriatric population.

 

Competitive Dashboard

• AstraZeneca (U.K),
• Bayer Pharma AG (Germany),
• Novartis AG (Switzerland),
• Daiichi Sankyo (Japan),
• Pfizer (U.S).

 

Drivers and Constraints Impacting the Market

With increasing consumption of alcohol and diabetic patients, the global stroke disorder and treatment market is likely to flourish. Also, the increasing prevalence of cardiovascular diseases is highly influencing the market across the globe. Brain problems and heart problems are considered as the most dangerous medical issues across the world with expensive medication and treatments. Thus, the market offering treatment for it is lucrative. The market is further accelerated by the huge patient pool along with rising geriatric population across the globe. Moreover, atrial fibrillation, hypertension, and coronary heart diseases are contributing to the growth of the market.

On the flip side, high cost of treatment adversely affects the growth of the market. Moreover, the lack of transparent reimbursement scenario is also likely to dampen the stroke disorder and treatment market during the assessment period.

Global Stroke Disorder and Treatment Market: Segmental Analysis

The global stroke disorder and treatment market has been segmented on the basis of type, medicine, treatment, and region.

By mode of type, the global stroke disorder and treatment market has been segmented into ischemic stroke and hemorrhagic strokes. Among these, the weakened blood vessel leakage is referred to as hemorrhagic stroke. Ischemic stroke generally occurs due to an obstruction within a blood vessel which supplies blood to the brain.

By mode of medicine, the global stroke disorder and treatment market has been segmented into anticoagulants/antiplatelet, anti-hypertensive.

By mode of treatment, the global stroke disorder and treatment market has been segmented into tissue plasminogen activator (TPA), carotid endarterectomy, surgical treatment, endovascular procedures, and others. TPA is referred to as an enzyme involved in the breakdown of blood clots and dissolves them. It is a less invasive procedure and is used for treating problems affecting the blood vessels like aneurysm.

Regional Insights

Geographically, the stroke disorder and treatment market span across regions namely, Europe, North America, Asia Pacific, and Rest-of-the-World.

Among these, the North America region is presumed to dominate the stroke diagnostics and therapeutics market and is likely to maintain its dominance. The growth is attributed to the rising awareness among the population regarding the symptoms of stroke followed by the several harmful effects associated with high glucose level in blood. With technological advancements and high-end research, and rising public interest, the demand for stroke disorder and treatment is likely to trigger in the coming years. Moreover, encouraging healthcare infrastructure and higher healthcare expenditure are some of the major factors contributing to the growth of the stroke disorder and treatment market.

European holds the second-largest position with high diabetic population. Moreover, the growing percentage of diabetes mellitus population is directly proportionate to the associated risk of stroke in individuals, thereby contributing to the market growth during the assessment period. Additionally, technological advancements and healthcare research are further influencing the market growth.

Industry Updates

CERENOVUS business has recently launched the single largest global registry, the EXCELLENT Registry, in order to collect and analyze stroke-inducing blood clots removed from the brain with its EMBOTRAP II Revascularization Device. The EXCELLENT Registry is likely to enroll up to 1000 ischemic stroke patients in as many as 50 clinical sites in Europe and the United States.

Access More Details of the Report @  https://www.marketresearchfuture.com/reports/stroke-disorder-treatment-market-1651 

CBD Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2026

CBD Market Overview

The Global CBD Market Growth is expected to register a CAGR of 125.58% to reach USD 22,07,162.54 Million by 2026.

Cannabidiol (CBD) is a safe, non-addictive substance found in the cannabis plant. CBD is the second-most abundant cannabinoid found in cannabis after tetrahydrocannabinol (THC). CBD has significant therapeutic benefits such as anti-inflammatory, analgesic, anti-anxiety, and seizure-suppressant properties. According to a survey by the National Center for Biotechnology Information (NCBI) conducted between 2017 and 2018, about 62% of the population used CBD to treat a medical condition.

The growing research & development and financial support by various private and government organizations for cannabinoid research, rising occurrence of chronic diseases and related complications, and legalization of CBD in various regions are expected to have a positive impact on the global cannabidiol (CBD) market. However, adverse effects associated with cannabis and stringent government policies are anticipated to restrain the growth of the global CBD market.

CBD Market Dynamics

Growing research and development activities and financial support by various private and government organizations for cannabinoid research- There are many private and government organizations supporting the research and development for cannabinoids for medical purposes. Cannabis has numerous medicinal properties by which it can cure various diseases. According to the National Institute of Drug Abuse, May 2018 publication, in 2017, the National Institute of Health (NIH) supported 330 projects and spent USD 140 million on cannabinoid research and development. During this investment, USD 36 million was spent on 70 projects to examine the therapeutic properties of cannabis, and USD 15 million was spent on 26 projects centered on cannabinoid (CBD). Even in 2016, NIH spent USD 21 million studying therapeutic properties of cannabinoids. Singapore, known for the world's most stringent drug laws, is also funding research projects on medical treatments containing synthetically derived compounds of the cannabis plant. In 2017, the government-run National Research Foundation launched a program to research the therapeutic potential of cannabinoids.

CBD Market Regional Analysis

The Americas dominate the global CBD market, owing to the increasing consumption of cannabis-based products. According to the World Health Organization (WHO), the consumption of marijuana has an annual prevalence rate of nearly 2.5% of the global population, i.e., approximately 147 million individuals. It is also reported that approximately 22.2 million Americans of 12 years of age and older use cannabis and related products for various reasons.

Europe holds the second largest market share due to the rising awareness about clinical applications of cannabis. CBD is legal and can be openly marketed in certain European countries, for instance, the Ministry of Agriculture, Food and Forestry, and the Bulgarian Food Safety Agency issued the ‘free certificate of sale’ for the CBD products. Thus, such approvals and consideration by the regulatory agencies in Europe are driving the CBD market growth in the region. In spite of the approvals and considerations, there are positive restrictions associated with the use of the products. For instance, in 2013, medical cannabis was legalized in the Czech Republic, but it was limited to 180 grams of dry matter per month. In Europe, marijuana and cannabis laws differ from country to country. Previously, Germany was importing medical cannabis from other countries, but in 2017, Germany passed a law to expand access to medical cannabis and to allow domestic production. Increasing participation of various companies such as Medical Marijuana Inc., as a scope of development, announced the formation of Canipa Holdings in Romania, European Union. The effect of such initiatives by the companies is facilitating the growth of the CBD market in the European region.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/8090 

The Asia-Pacific region is classified into CBD Market China, CBD Market India, CBD Market Japan, and Rest of Asia-Pacific. It holds the third largest position in the CBD market. Recently, China has legalized the cultivation of CBD (Hemp) and extraction for the derived product. The products are exported and not sold in China. Yunnan provincial government and Public Security Bureau approved the first industrial hemp plant extraction factory in China. It is the largest country in terms of area, population, businesses, and others. The entry of Chinese companies in the CBD market has created a great potential for expansion and growth. In Asia-Pacific, cannabis-based products are completely unacceptable. But due to the increasing cases of epilepsy, cannabis-based products are prescribed by some physicians. For instance, a recent Australian nationwide survey of 976 people with epilepsy indicated that 13% of the parents were using illicit cannabis extracts to manage their child’s seizures. Australia mainly focuses on the medical use of cannabis products. Australian regulatory agencies are operating on providing a guideline for the use of the CBD products. This is expected to help in the growth of the CBD market in Australia.

The Middle East and Africa is expected to witness a restricted growth due to stringent government policies, adverse effects associated with cannabis, and the illegal use of marijuana. In the Middle East, few of the Arab countries are imposing trick laws over the use and handling of cannabis-related products. Thus, the CBD market in these regions has limited scope for growth during the forecast period.

Segmentation

On the basis of form, the global cannabidiol market is segmented into solid and liquid.

In the solid form of CBD, the report covers CBD crystals, CBD wax, capsule/softgel, hash, and others. The liquid form of CBD includes CBD oil, tincture, cream, e-liquid, and others.

CBD crystals are a pure form of CBD isolates. CBD crystals are produced by heating CBD rich extract and then continuous cooling and separating it. CBD crystals are generally used to manufacture CBD infused edibles and creams. CBD wax is solidified or crystalized full spectrum form of CBD. CBD wax is a highly concentrated form of CBD and especially used for pain relief. CBD capsules are similar in comparison to capsules as they are surrounded by an outer shell, usually gelatin. CBD soft gelatin capsule is a translucent golden shade standard capsule that is filled with hemp oil and sometimes olive oil as filler.

CBD oil is one of the most popular and widely available forms of CBD. It is specifically used for medical purposes as it provides fast and effective results. There are a wide variety of flavors of full spectrum CBD oils available in the market. CBD tinctures are made from high strains of hemp, with 60-70% of alcohol. CBD tinctures are primarily used to relieve anxiety and ease the pain. CBD infused e-liquid are used as a fluid in electronic cigarettes and vaporizers.

CBD Market Key Players

The prominent players in the global CBD market are Aphria Inc., Folium Biosciences, Freedom Leaf, Inc, Green Roads of Florida, LLC, CBD Health Solutions, LLC, ENDOCA, Isodiol International Inc, CV Sciences, Inc, Medical Marijuana, Inc., Canopy Growth Corporation, Elixinol Global Limited.

The players operating in the global CBD market are focusing on product launches, along with expanding their global footprints by entering untapped markets.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cbd-market-8090 

ICP-OES Spectrometer Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2025

ICP-OES Spectrometer Market Highlights:

ICP-OES Spectrometer is an analytical instrument that is used for the detection of chemical elements. It uses the technique of inductively coupled plasma optical emission spectroscopy (ICP-OES) for carrying out its analysis procedure. Certain factors that propel the growth of the ICP-OES spectrometer market include increasing R&D expenditure for the development of better analytical systems and growing technological advancements.

However, the high cost of instruments and requirement of large capital investment for setting up instrument manufacturing plants is hindering the growth of the global ICP-OES spectrometer market in the forecast period.

The Global ICP-OES Spectrometer Market size is expected to register a CAGR of 7.2% during the forecast period of 2019 to 2025 with a market value of USD 521.4 million in 2018.

Currently, the global ICP-OES spectrometer market is dominated by several players. The major players in this market are involved in strategic acquisitions and product launches to expand their product portfolios. For instance, in March 2016, GBC Scientific Equipment launched the OptiMass 9600, which uses the ICP-OES spectrometer technology.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/8120 

Key Players:

Some of the key players in the global ICP-OES spectrometer market are PerkinElmer Inc. (US), Shimadzu Corporation (Japan), GBC Scientific Equipment (Australia), Thermo Fisher Scientific (US), Agilent Technologies, Inc. (US), SPECTRO Analytical Instruments GmbH (Germany), Teledyne Leeman Labs (US), Analytik Jena AG (Germany), Horiba (Japan), Skyray Instrument Inc. (US), Beijing Huake Tiancheng Technology Co., Ltd (China), FPI (China), Hitachi High-Technologies Corporation (Japan), Merck KGaA (Germany), and others.

Segmentation:

The global ICP-OES spectrometer market has been segmented based on spectrometer type, application, and end user.

The market, based on spectrometer type, has been bifurcated into sequential and simultaneous. The sequential spectrometer market is expected to hold a major share in the market owing to its wider availability in the market. The simultaneous spectrometer segment is anticipated to be the fastest growing due to its rising adoption rate.

The market, by application, has been divided into nanotechnology, drug discovery, environmental testing, food & agriculture, and others. The drug discovery segment is expected to hold a major share owing to a large number of applications of ICP-OES spectrometer in this field. The environmental testing segment is expected to be the fastest growing due to an increasing number of research activities for using ICP-OES spectrometer for environmental testing purpose.

The market, by end user, has been classified as pharmaceutical & biotechnology companies, research & academic institutes, and others. Pharmaceutical & biotechnology companies are anticipated to hold a major share in the market. This is due to the increasing number of applications of ICP-OES spectrometer in the pharmaceutical industry. The research & academic institutes segment is expected to become the fastest growing market due to the increasing research activities.

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ICP-OES spectrometer market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European ICP-OES spectrometer market has been sub-divided Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The ICP-OES spectrometer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The ICP-OES spectrometer market in the Middle East & Africa has been divided into the Middle East and Africa.

Regional Analysis:

The market in the Americas is expected to dominate the global ICP-OES spectrometer market due to the growing expenditure on R&D to develop new technologies and the high adoption of new technology in the region. Moreover, the presence of major companies such as PerkinElmer Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, etc. in North America is also expected to fuel the market growth in the region.

The market in Europe showed a substantial amount of growth. The market growth in this region can be attributed to the presence of a well-established healthcare system and increasing adoption of ICP-OES spectrometer for research purposes.

The market in Asia-Pacific is projected to have the fastest growth rate during the forecast period owing to the rapid growth of the pharmaceutical industry in countries such as China, India, and Japan.

The market in the Middle East & Africa is anticipated to account for the least share of the global market due to low disposable income in the region. Moreover, the presence of major companies in the Middle East and African market is also limited, which is projected to curb the growth of the market in the future.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/icp-oes-spectrometer-market-8120 

Worldwide Laboratory Informatics Market Booming Industry Size And Revenue | Future Vision Footbridge 2024 In Healthcare Sector

Laboratory Informatics Market Highlights:

The global laboratory informatics market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 2422 million in 2018 and is projected to register a CAGR of 7.2% over the forecast period.

The increasing participation of key players is one of the key factors driving the market, says MRFR’s Laboratory Informatics market insights. In 2018, Abbott Laboratories announced the launch of the STARLIMS Quality Manufacturing Solution QM 11.1 to support laboratory productivity and efficiency across diverse sectors of the global manufacturing industry.

Various other factors such as the increase in adoption of cloud-based platforms by CROs, increasing preference towards personalized medicine, untapped emerging markets, rise in regulatory approvals, and rising R&D in the field of meadicine are also expected to propel the growth of the market.

However, high maintenance and service costs can hamper market growth over the forecast period.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/8106 

Key Players:

Some of the key players in the global laboratory informatics market are Agilent Technologies, Inc., Abbott Laboratories, Accelerated Technology Laboratories, Cerner Corporation, Dassault Systèmes, IDBS, KineMatik, Lablynx, Inc., Labvantage Solutions, Inc., Autoscribe Limited, Labware, Labworks LLC, McKesson Corporation, Thermo Fisher Scientific Inc., Perkinelmer Inc., Waters, and others.

Segmentation:

The global laboratory informatics market is segmented based on product, component, deployment model, end user, and region.

The global market for laboratory informatics, by product, is segmented into Laboratory Information Management Systems (LIMS), Chromatography Data Systems (CDS), Electronic Lab Notebooks (ELN), Electronic Data Capture (EDC) & Clinical Data Management Systems (CDMS), Laboratory Execution Systems (LES), Enterprise Content Management (ECM), and Scientific Data Management Systems (SDMS). The Laboratory Information Management Systems (LIMS) segment is further classified as broad-based LIMS and industry-specific LIMS.

Based on component, the market is segmented into software and services.

Based on the deployment model, the market is segmented into on-premise models, cloud-based models, and remotely hosted models.

Based on end user, the market is segmented into life sciences companies, CROs, environmental testing laboratories, and others.

In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.

The laboratory informatics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European laboratory informatics market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The laboratory informatics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The laboratory informatics market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Analysis:

The Americas dominated the global market for laboratory clinical informatics owing to the escalating healthcare cost coupled with the rising pressure to bend the cost curve resulted in increased regional adoption of laboratory information management systems. According to the Organization for Economic Co-Operation and Development, in 2018, Americans spent USD 3.65 trillion on healthcare. It is also stated that the level of spending is by far the highest in the developed world.

In 2018, it was estimated that Europe stood second in the global laboratory informatics market. Technological advancements, along with the availability of funding opportunities in research and innovation, will support the growth of healthcare laboratory informatics. Germany commanded the largest share in the European market for medical laboratory informatics due to growing automation of laboratory systems.

Asia-Pacific (APAC) is expected to represent the phenomenal growth in medical informatics throughout the forecast period due to rising participation of market players and increasing healthcare funding. In 2018, Sysmex Corporation, Japan-based company, launched a new network solution Caresphere. The solution is designed to provide new value through the intelligent use of information by people involved in testing and healthcare.

On the other hand, the Middle East and Africa held the least share in the global Laboratory Informatics market due to the low economic development, especially within the African region.

Browse Laboratory Informatics Market Research Report with Information by Product, Component, Deployment Model, End User and Region @ https://www.marketresearchfuture.com/reports/laboratory-informatics-market-8106

 

Global Genetic Testing Market Growth Factors, Types And Application By Regional Analysis 2024

Market Synopsis of Global Genetic testing Market:

Genetic Testing Market is expected to grow at CAGR of 11.50% to reach USD 22834.19 million till 2024, revealed by Market Research Future (MRFR) with Global Genetic Testing Market Analysis by by Type, Method, by Application, and Regions - Americas, Europe, Asia-Pacific and Middle East & Africa and Forecast till 2024

Key Players

The prominent players in the global genetic testing market are Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Illumina Inc. (US), Myriad Genetics, Inc. (US), PerkinElmer Inc. (US), QIAGEN N. V.  (Germany), Quest Diagnostics Incorporated (US), Eurofins Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Blueprint Genetics (Finland), BGI Genomics (China), and Thermo Fisher Scientific Inc. (US).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2009

Market Insights:

Genetic testing is also known as DNA testing. Genetic tests involve a set of lab tests for the study of the genetic makeup of patients and identify any gene mutations and alterations in the healthy structure of DNA leading to the development of genetic disorders.

Some of the protuberant drivers supporting the growth of the global genetic testing market are identified as raising awareness about the benefits of genetic testing and the rising prevalence of genetic disorders.

Additionally, the role of genetic tests in forensic investigations and change in the trend of the genetic testing industry from service-driven to product-driven industry are expected to drive the global genetic testing market in the coming years.

Genetic testing offers a lot of benefits such as the chance for taking preventive measures to avoid potential diseases and lead a healthy life, knowledge about genetic alterations in the fetus that may lead to abnormal growth, and aids forensic investigations, among others. Due to the great benefits provided by these tests, people are getting more aware of them. This phenomenon intrigues people to go for tests to understand their genetic structure and possible disorders they may have to go through. The growing awareness has gathered a lot of audience for the genetic testing market and has also positively impacted the growth of this market.

Moreover, there has been tremendous growth in the prevalence of genetic disorders which may be due to various reasons such as geographical and environmental changes, change in food habits, pollution, and exposure to harmful radiations or chemicals. Genetic tests are also used to analyze family relations such as father, mother, half-brother, half-sister, and others. Forensic science and genetic testing have aided law and order to a great extent. With an increasing number of companies entering into this segment, the overall market for genetic tests has increased and expected to grow fast in the near future.

Some of the key strategies followed by the players operating in the global genetic testing market were innovation, product development, acquisition, and expansion.

• In April 2017, Myriad Genetics, Inc. signed an agreement with Clovis Oncology for the use of its FDA-Approved BRACAnalysis CDx Test to identify patients with germline BRCA Mutations for the Rubraca (rucaparib) treatment.
• In January 2017, Bio-Rad Laboratories, Inc. announced the launch of the Single Cell Sequencing Solution in collaboration with Illumina Inc.
• In August 2016, Abbott Laboratories launched Alinity, a family of next-generation system.

Segmentation                                                                                                                                        

Global genetic testing Market, by type, segmented into prescribed genetic testing and direct to consumer genetic testing. Prescribed genetic testing is the leading segment, which is growing at the highest CAGR to reach USD 21653.91 million by the end of 2024. Its large market share is majorly attributed to the widespread availability and service providers of various genetic tests and less availability of direct to consumer tests in all parts of the world.

Based on method, the genetic testing market is segmented into molecular genetic tests/ DNA tests, chromosomal genetic tests, and biochemical genetic tests. The molecular genetic test/DNA tests account for major share with 11.78% CAGR during the forecast period. Molecular testing helps to determine the sequence in DNA or RNA related to a particular disease.

The genetic testing market, by application, is segmented into reproductive health, cancer screening, ancestry, predictive and pre-symptomatic testing, and others. The reproductive health segment accounted for the largest market share of 33.61% in 2018.

Browse Genetic Testing Market Research By Type, Method, by Application and Region @ https://www.marketresearchfuture.com/reports/genetic-testing-market-2009

Regional Analysis         

The Americas accounted for the largest market share of the global genetic testing market, by region in 2018. This large share is majorly due to high awareness about genetic testing, high disposable income of the population, and implementation of newborn screening in the majority of the hospitals in the region. In 2015, approximately 12 million Americans suffered from genetic diseases which are approximately 1 in 20 people.

Europe accounted for the second largest market share. Technological advances, well-developed health care sector, and governmental support for the research and development of different tests and devices have provided fuel for the growth of the market. Germany commands the largest market share in the Europe genetic testing market.

Asia-Pacific is the fastest growing region for genetic testing. The presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the Asia-Pacific genetic testing market. The Middle East & Africa accounted for the 8.8% market share in 2018.

The Over-the-Wire Micro-Guide Catheter Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2023

Over-the-wire Micro Guide Catheter (OTW Micro Guide Catheter) is a thin tubular Medical device inserted into the body for diagnosis or treatments of diseases like cardiovascular, neurovascular, and urology. Specially designed to ease complex procedures, OTW Micro Guide Catheter combining excellent cross-ability and optimal guide-wire support, can effectively treat challenging cases involving tortuous vessels, CTO (chronic total occlusions), bifurcations, and highly stenosed and calcified lesions, giving the high success rate.

OTW Catheters are widely used in cardiovascular applications such as peripheral and coronary interventions and neurovascular interventional applications. The high success rate associated with the use of these catheters further augments its uptake and demand, resultantly driving its market growth.

According to Market Research Future (MRFR)’s global Over-the-wire Micro Guide Catheters market Size Forecast, the industry is expected to grow at a CAGR of 9.37% during the forecast period (2018–2023).

According to reports published by the Centers for Disease Control and Prevention, the coronary heart disease is the most common type of heart diseases that accounted for the death of about 366,000 people in 2015.

Over-the-wire catheters comparatively make a better choice to treat a brain aneurysm than the rapid exchange catheters owing to their capabilities of extra pushing to enter stenose vessels, and additional support that they provide.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6078

The increasing occurrences of coronary heart diseases, neurovascular diseases, hypertension, and other metabolic disorders, raising awareness for health, advancement in technologies, good healthcare infrastructure, and favorable reimbursement policies are fueling the market growth. 

Regional Analysis

The global over-the-wire micro guide catheters market is segmented into four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas is the global market leader for over-the-wire Micro-guide catheters. As per the study published in the Surgical Neurology International in 2017, it was found that more than 3% population of the United States equivalent to nearly 10 million individuals have a brain aneurysm. North America commands for the major share of the market whereas; South America show the fastest growth of the market due to the presence of boundless growth opportunities.

Europe OTW Micro Guide Catheter market holds the second position, globally. This is primarily attributable to the increasing prevalence of obesity as well as the increased incidence rate of hypertension and diabetes, which in turn is escalating cardiovascular traumas and cardiac arrest. Each year 15% of deaths in Europe occur due to cardiovascular diseases claims a study conducted by European Society of Cardiology.

The Asia Pacific region is the fastest growing market for the over-the-wire micro guide catheters. The region presents significant growth opportunities for market players as local policy makers continue to restructure the policy framework for the healthcare sector.

Global OTW Micro Guide Catheter Market: Segmentation

The global over-the-wire micro guide catheters market is segmented on the basis of applications and end-users. On the basis of applications, it is segmented into cardiovascular and neurovascular. By the cardiovascular, it is segmented into angiography, angioplasty, peripheral stenting, and others. On the basis of the neurovascular, it is segmented into intracranial aneurysms, percutaneous neurointerventional procedures, and others. Based on end-user the market is segmented into hospitals & clinics, ambulatory surgical centers, research & academic institutes, and others.  

Major Players in the Over-the-wire Micro Guide Catheters Market

Enki – Microtubes, Cardinal Health, DePuy Synthes, Koninklijke Philips N.V, Penumbra Inc., Terumo Europe N.V., Integer Holdings Corporation, Merit Medical Systems Inc., Teleflex Incorporated, Cook Medical, Boston Scientific Corporation, Asahi Intecc Company Limited, and Medtronic plc.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/over-the-wire-micro-guide-catheter-market-6078

Global Herbal Medicine Market Positive Growth And Forecasts By 2023

The Global Herbal Medicine Market value is expected to register a CAGR of 5.88% to reach USD 1,29,689.3 million by 2023.

Herb is a plant or plant part used for its scent, flavor, or therapeutic properties. Herbal medicines are a type of dietary supplements. They are sold as tablets, capsules, powders, teas, extracts, and fresh or dried plants. People use herbal medicines to maintain and improve their health. Many conventional drugs originate from plant sources, and most of the few effective drugs are plant-based. Examples include aspirin (from willow bark), digoxin (from foxglove), quinine (from cinchona bark), and morphine (from the opium poppy). The development of drugs from plants continues, with drug companies engaged in the large-scale pharmacologic screening of herbs.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/3250

Key Players

The prominent players in the global herbal medicine market are Arkopharma, Bayer AG, BEOVITA, Hishimo Pharmaceuticals, Schaper & Brümmer, ZeinPharma Germany GmbH, Venus Pharma GmbH, Dasherb Corp, and Arizona Natural Products among other.

Some of the key strategies followed by the players operating in the global herbal medicine market were innovation, product development, acquisition, and expansion.

Market Dynamics

Herbal medicines are used since ancient times for numerous health conditions. It is the oldest and most extensively used system of medicine in the world today. There are various kinds of herbal medicines and supplements used across the world. According to the National Center for Biotechnology Information, 2015, the World Health Organization (WTO), reported that around 70% to 80% of people globally rely on herbal sources for their treatment. Also, according to the American Botanical Council, September 2017, it was reported that in 2016, the sale of herbal supplements increased by 7.7% in the US. It was also estimated that consumers spending on herbal supplements increased to USD 7.452 billion in 2016. Thus, the increase in the demand for herbal products for healthcare purposes is likely to enhance this market during the forecast period.

Segmentation

The global herbal medicine Market, by category, is segmented into herbal pharmaceuticals, herbal dietary supplements, herbal functional foods, and herbal beauty products. The herbal pharmaceutical segment led the herbal medicine market with USD 50,972.4 million in 2017. The herbal pharmaceutical segment is growing owing to the increasing research and development on various herbs to find their medicinal properties, growing demand for natural medicines having fewer side-effects, and rising prevalence of chronic diseases such as diabetes, arthritis, cancer, sleep disorders, and digestive problems.

Marrubium vulgare segment is the fastest-growing segment of the market at CAGR of 6.45% during the forecast period. Marrubium vulgare also known as white horehound is a largely cultivated plant, and its above-ground parts are used for medicinal use. The upper part of the plant is used in powder, liquid extract, or juice form for medicinal purposes. Marrubium vulgare is largely used for digestion problems which include indigestion, loss of appetite, gas, bloating, diarrhea, constipation, and gallbladder complaints. It is also used for the treatment of breathing problems

The global herbal medicine Market, by form, is segmented into extracts, powders, capsules and tablets, syrups, and others. The extracts segment accounted for the largest market share of 36.95% in 2017.

The global herbal medicine Market, by source, is segmented into leaves, fruit, roots, and barks whole plant, and others (combinations of various plant parts). On the basis of source, the leaves segment is expected to lead the global herbal medicine market. The leaves segment held a share of USD 51,495.2 million in 2017.

The global herbal medicine Market, by distribution channel, is segmented into hospital and retail pharmacies, e-commerce, and others. The hospital & retail pharmacies segment accounted for the largest market share of 55.82% in 2017. The growing prevalence of cancer and infectious diseases across the globe, improving healthcare infrastructure, and skilled professionals are driving the growth of hospital and retail pharmacies in the herbal medicine market.

Regional Analysis

Europe is expected to account for the largest market share owing to extensive R&D for herbal medicine, increasing funding for research on medicinal plants, and growing preference for herbal drugs globally. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead market growth during the forecast period. The increasing prevalence of chronic diseases and rising government support facilitate market growth within the region.

Americas accounts for the second largest share in the global herbal medicine market. It accounted for a considerable market share of 16.2% as of 2017. The use of herbal medicines is also growing in the US after conducting the first national study of alternative and complementary medicines used by Eisenberg et al. According to the National Center for Biotechnology Information 2017, it was reported that herbal supplements were majorly used for conditions such as cancer (43.1%), stroke (48.7%), and arthritis (43%) in the US. Such a high demand and preference for herbal products is likely to boost the market growth during the forecast period.

Asia-Pacific is expected to register a CAGR of 5.99% during the forecast period owing to the adoption of traditional medicines by pharmaceutical companies, researchers, and policymakers. On the other hand, the Middle East and Africa are expected to observe a slow growth due to less awareness and in-depth knowledge about herbal drugs in this region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/herbal-medicine-market-3250